Streetbeat News

Analyst Ratings

GEV

BMO Capital has initiated coverage on GE Vernova with an Outperform rating and set a price target of $245.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 10:10 am

DRI

Stephens & Co. analyst Jim Salera maintains an Equal-Weight rating on Darden Restaurants (NYSE:DRI) but lowers the price target from $165 to $159.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 10:09 am

GEVO

HC Wainwright & Co. has reiterated its Buy rating for Gevo, maintaining a price target of $14. Analyst Amit Dayal continues to support the stock, indicating confidence in its future performance.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 10:05 am

ADBE

Piper Sandler analyst Brent Bracelin has reiterated an Overweight rating on Adobe (NASDAQ:ADBE) and maintained a price target of $635.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 10:02 am

MPW

Colliers Securities has upgraded Medical Properties Trust (NYSE:MPW) from Neutral to Buy, setting a price target of $6.5.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 9:57 am

EOLS

Needham analyst Serge Belanger has reiterated a Buy rating on Evolus (NASDAQ:EOLS) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 9:51 am

CWEN

D

UGI

Analysts have provided updated ratings and price targets for three high-yield utilities stocks: UGI Corporation, Clearway Energy, and Dominion Energy. UGI has mixed ratings with a recent profit report, Clearway Energy was upgraded despite declining sales, and Dominion Energy missed revenue expectations but received upgraded ratings.

Portfolio Pulse from Avi Kapoor

September 13, 2024 | 9:51 am

IMRX

Needham analyst Ami Fadia has reiterated a Buy rating on Immuneering (NASDAQ:IMRX) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 9:42 am

TENB

Needham analyst Mike Cikos has reiterated a Buy rating on Tenable Holdings (NASDAQ:TENB) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 9:37 am

KIDS

Needham analyst Mike Matson has reiterated a Buy rating on OrthoPediatrics (NASDAQ:KIDS) and maintained a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 9:32 am